PARP1 and tuberculosis: First, our finding that adjunctive PARP inhibition with Tp dampened TB immune responses and potently reduced pathology in mouse lungs suggests that the addition of non-antimicrobial PARP1 inhibitors as adjunctive therapy may benefit the treatment of TB by reducing lung disease.